MiNK Therapeutics (INKT) Selected for ARPA-H BoSS Initiative

MiNK Therapeutics was selected as a therapeutic cell platform for an ARPA-H BoSS team aiming to enable room—temperature cell therapy storage; ARPA-H has committed up to $87M across the four-year program.Material DetailsContext by AI AnalystThis is an early-stage strategic validation aligning MiNK’s…